NPS Pharmaceuticals (NPSP) +8.3% premarket after the company and drug partner Takeda (TKPHF.PK)...

|About: NPS Pharmaceuticals, Inc. (NPSP)|By:, SA News Editor

NPS Pharmaceuticals (NPSP) +8.3% premarket after the company and drug partner Takeda (TKPHF.PK) say a European panel recommended their Revestive drug receive marketing approval as a once-daily treatment for adults with short bowel syndrome.